Latest Exosome Stories
NEW YORK, April 29, 2013 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine, today announced that Kapil Dhingra, M.D., has been named chairman of Exosome Diagnostics Board of Directors. Dr. Dhingra, 52, has served as a member of Exosome's board of directors since March 2012. He has significant experience transforming oncology therapeutic and diagnostic development programs into products available...
SAN DIEGO, April 18, 2013 /PRNewswire/ --Aethlon Medical, Inc. (OTCBB: AEMD), disclosed that a poster presentation entitled: "Extracorporeal Exosome Removal: A Therapeutic Strategy to Address an Evolutionary Survival Mechanism Shared by Cancer and Infectious Viral Pathogens," is being presented today at the International Society of Extracellular Vesicles (ISEV) 2013 conference being held in Boston, MA. Dr. Annette Marleau, Director of Tumor Immunology at Aethlon Medical will give...
"Current wisdom says that cells are closed entities that communicate through the secretion of soluble signalling molecules. Recent findings indicate that cells can exchange more complex information – whole packages of genetic material and signalling proteins. This is an entirely new conception of how cells communicate", says Dr Mattias Belting, Professor of Oncology at Lund University and senior consultant in oncology at Skåne University Hospital, Lund, Sweden. Exosomes are small...
SAN DIEGO, April 16, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. As disclosed in yesterday's SEC form 8-K submission, we entered into a subcontract agreement with Battelle Memorial Institute (Battelle) to provide services underlying a $22.8 million prime contract that was recently awarded to Battelle by the Defense Advanced Research Projects Agency (DARPA). The objective of this contract...
NEW YORK, April 16, 2013 /PRNewswire/ -- Exosome Diagnostics, a developer of biofluid-based molecular diagnostic products for use in personalized medicine, today announced data demonstrating exosome technology performance in clinical applications which will be presented at the International Society for Extracellular Vesicles 2013 (ISEV 2013) annual meeting, April 16-20, in Boston. The ISEV meeting is the preeminent international conference in the rapidly growing field of exosome and...
NEW YORK, April 8, 2013 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostics for use in personalized medicine, today announced that the company is presenting a late-breaking abstract at the AACR Annual Meeting 2013, in Washington D.C. The abstract is titled "Exosome profiling of mRNAs and miRNAs in serum samples from GBM (glioblastoma multiforme) patients." It will be presented during Poster Session 47 from 1 to 5 p.m. EDT on April 8 by...
Exosomes and Microvesicles, the Official Journal of the American Society for Exosomes and Microvesicles, to Provide Scientific Community New Access to Ground-Breaking Research RIJEKA, Croatia, April 8, 2013 /PRNewswire/ -- InTech Open Access publisher is pleased to announce the collaboration with the American Society for Exosomes and Microvesicles (ASEMV) to publish the scientific journal Exosomes and Microvesicles, a peer-reviewed publication designed to bring together exosomes...
In a first-of-its-kind experiment using microvesicles generated from mesenchymal bone marrow cells (MSCs) to treat cancer, neurological researchers at Henry Ford Hospital have discovered a novel approach for treatment of tumors. Specifically, the research team found that introducing genetic material produced by MSCs significantly reduced a particularly resistant form of malignant brain tumor in living lab rats. Detroit, Michigan (PRWEB) April 01, 2013 DETROIT – In a first-of-its-kind...
New England Peptide acquires next generation exosome and microvesicle affinity technology for potential detection of cancer and other diseases. Gardner, MA (PRWEB) March 07, 2013 New England Peptide, Inc. (NEP) today announced that it has entered into a licensing agreement with the Atlantic Cancer Research Institute (ACRI). Under the terms of the agreement NEP has acquired the worldwide exclusive rights for Vn96 and a portfolio of other peptide compounds to be used for the research grade...
SAN DIEGO, Feb. 28, 2013 /PRNewswire/ --Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. I recently attended a healthcare related event that featured a panel discussion comprised of life science bankers and venture capitalists. While members of this panel often had differing viewpoints, they did mutually agree they were interested in emerging therapeutic candidates that provided more than one "shot on goal," meaning...
